Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2028

Conditions
Central Nervous System Lymphoma
Interventions
DRUG

lenalidomide

Patients with MRI documented response CR or PR after induction chemotherapy will enter the study protocol of lenalidomide maintenance (at a dose of 15 mg per day, on days 1 to 21 of each 28-day cycle) for up to 12 cycles or until the patients withdrew consent, the disease progressed, or unacceptable toxic effects occurred.

Trial Locations (1)

13620

RECRUITING

Seoul National University Bundang Hospital, Seongnam-si

All Listed Sponsors
collaborator

Samyang BioPharm

UNKNOWN

lead

Seoul National University Bundang Hospital

OTHER